menu search

IDNA / IDNA: Continues To Underperform, But With Long-Term Potential

IDNA: Continues To Underperform, But With Long-Term Potential
I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive growth since its inception in 2019, IDNA has experienced a downward trajectory since 2021, with its current price lower than at inception. The healthcare industry is predicted to be the fastest growing industry in the US in 2023, with a 15% growth rate expected by 2027, making it a profitable long-term investment space. Read More
Posted: Jun 8 2023, 04:03
Author Name: Seeking Alpha
Views: 081471

IDNA News  

IDNA: Continues To Underperform, But With Long-Term Potential

By Seeking Alpha
June 8, 2023

IDNA: Continues To Underperform, But With Long-Term Potential

I rate IDNA a Hold due to its focus on biotech stocks with long-term growth potential in a rapidly growing healthcare industry. Despite impressive gro more_horizontal

IDNA: Healthcare Dashboard For February

By Seeking Alpha
February 16, 2023

IDNA: Healthcare Dashboard For February

Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. more_horizontal

IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally

By Seeking Alpha
April 29, 2022

IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity mark more_horizontal


Search within

Pages Search Results: